[4-chloro-2-(4-chloro-3-cyclohexylsulfamoyl-phenyl)-1H-indol-3-yl]-acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: [4-chloro-2-(4-chloro-3-cyclohexylsulfamoyl-phenyl)-1H-indol-3-yl]-acetic acid
• 英文别名: 2-[4-chloro-2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-1H-indol-3-yl]acetic acid
• 化学式: C₂₂H₂₂Cl₂N₂O₄S
• 分子量: 481.4
• InChiKey: OAFWQOKONGHPNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  氢氧化钾 、 [4-chloro-2-(4-chloro-3-cyclohexylsulfamoyl-phenyl)-1H-indol-3-yl]-acetic acid 在 乙醇 作用下， 反应 0.17h， 生成 potassium (4-chloro-2-(4-chloro-3-cyclohexylsulfamoyl-phenyl)-1H-indol-3-yl)-acetate
  参考文献：
  名称：

  WO2008/14186

  摘要：

  公开号：
• 作为产物：
  描述：

  [4-chloro-2-(4-chloro-3-cyclohexylsulfamoyl-phenyl)-1H-indol-3-yl]-acetic acid ethyl ester 在 甲醇 、 lithium hydroxide 、 水 、 氢氧化钾 、 盐酸 作用下， 反应 20.0h， 生成 [4-chloro-2-(4-chloro-3-cyclohexylsulfamoyl-phenyl)-1H-indol-3-yl]-acetic acid
  参考文献：
  名称：

  WO2008/14186

  摘要：

  公开号：

文献信息

• 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：YANG Zhaoxia

  公开号：US20090176804A1

  公开（公告）日：2009-07-09

  The present invention is directed to 2-phenyl-indole compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, eczema, urticaria diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.

  本发明涉及2-苯基吲哚化合物、它们的制备、含有这些化合物的制药组合物，以及它们在治疗患有PGD2介导的疾病的患者中的制药用途，包括但不限于过敏性疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身性肥大细胞增多症、伴随全身性肥大细胞激活的疾病、过敏性休克、支气管痉挛、支气管炎、湿疹、荨麻疹等伴随瘙痒的疾病（如特应性皮炎和荨麻疹）、因瘙痒引起的继发性疾病（如白内障、视网膜脱离、炎症、感染和睡眠障碍）、炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、慢性类风湿性关节炎、胸膜炎、溃疡性结肠炎等。
• [EN] 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS<br/>[FR] 2-PHÉNYL-INDOLES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA PROSTAGLANDINE D2
  申请人：SANOFI AVENTIS

  公开号：WO2008014186A1

  公开（公告）日：2008-01-31

  [EN] The present invention is directed to 2-phenyl-indole compounds (A), their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, eczema, urticaria diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.
  [FR] La présente invention concerne des composés de 2-phényl-indole (A), leur préparation, des compositions pharmaceutiques contenant ces composés et leur utilisation pharmaceutique pour traiter un patient qui présente un trouble induit par la PGD2 y compris, mais non limitativement, une maladie allergique (telle que la rhinite allergique, la conjonctivite allergique, la dermatite atopique, l'asthme bronchique et l'allergie alimentaire), la mastocytose systémique, les troubles accompagnés de l'activation des mastocytes systémiques, le choc anaphylactique, la bronchoconstriction, la bronchite, l'eczéma, les maladies de type urticaire accompagnées de démangeaisons (tels que la dermatite atopique et l'urticaire), des maladies (telles que la cataracte, le détachement rétinien, l'inflammation, l'infection et les troubles du sommeil) qui sont le résultat d'un comportement lié aux démangeaisons (tel que le fait de se gratter ou de se taper), l'inflammation, la bronchopneumopathie chronique obstructive, les lésions d'ischémie-reperfusion, un accident vasculaire cérébral, la polyarthrite chronique rhumatismale, la pleurésie, la rectocolite hémorragique et des maladies similaires.
• WO2008/14186
  申请人：——

  公开号：——

  公开（公告）日：——